Advertisement

Obesity Surgery

, Volume 19, Issue 9, pp 1313–1323 | Cite as

Adipokine Serum Levels Are Related to Liver Histology in Severely Obese Patients Undergoing Bariatric Surgery

  • Marianna Argentou
  • Dina G. TiniakosEmail author
  • Menelaos Karanikolas
  • Maria Melachrinou
  • Maria G. Makri
  • Christos Kittas
  • Fotis Kalfarentzos
Clinical Research

Abstract

Background

Leptin, adiponectin, and resistin are adipokines linked to the development of insulin resistance, which plays a central role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We aimed to define adipokine serum levels in severely obese patients undergoing bariatric surgery and to correlate these with anthropometric and metabolic variables, liver function tests, and histopathological parameters of NAFLD and nonalcoholic steatohepatitis (NASH).

Methods

Surgical liver biopsies were obtained from 50 bariatric patients with no history of liver disease or significant alcohol consumption. Serum leptin, adiponectin, and resistin levels were measured, and histology was assessed using Brunt’s and Kleiner’s scoring systems.

Results

Waist/hip ratio was significantly higher in men (p = 0.0001), and leptin (p = 0.036) and adiponectin (p = 0.0001) serum levels were higher in women. Forty-one of 50 patients (82%) had histological NAFLD, including 10 (20%) with NASH. Nine patients (18%) had normal liver histology (obese control subgroup). In NAFLD patients, serum adiponectin was negatively correlated with activity grade and fibrosis stage, resistin was negatively correlated with steatosis grade (p = 0.033), while leptin was not related to histology. Leptin/adiponectin ratio showed positive association with stage (p = 0.044). In the subgroup of NASH patients, adiponectin was negatively correlated only with stage (p = 0.01), while there was no correlation between leptin, resistin, or leptin/adiponectin and histology.

Conclusions

Serum adiponectin and resistin levels are related to liver histology in bariatric patients and may be indicative of the histological severity of NAFLD and the extent of hepatic steatosis, respectively. Serum leptin levels are not informative of underlying liver histology in severely obese patients.

Keywords

Adipokines Leptin Adiponectin Resistin Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Obesity Bariatric surgery 

References

  1. 1.
    Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol. 2007;23:193–8.CrossRefGoogle Scholar
  2. 2.
    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefGoogle Scholar
  3. 3.
    Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin N Am. 2007;91:1125–49.CrossRefGoogle Scholar
  4. 4.
    Lee S, Jin KY, Yong JT, et al. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study. Scand J Gastroenterol. 2006;41:566–72.CrossRefGoogle Scholar
  5. 5.
    Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.CrossRefGoogle Scholar
  6. 6.
    Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–6.CrossRefGoogle Scholar
  7. 7.
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.CrossRefGoogle Scholar
  8. 8.
    Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191–207.CrossRefGoogle Scholar
  9. 9.
    Srivastava S, Younossi ZM. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. Hepatology. 2005;42:490–2.CrossRefGoogle Scholar
  10. 10.
    de Freitas AC, Campos AC, Coelho JC. The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2008;11:267–74.CrossRefGoogle Scholar
  11. 11.
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;3:1202–19.CrossRefGoogle Scholar
  12. 12.
    Yeh M, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007;128:837–47.CrossRefGoogle Scholar
  13. 13.
    Wieckowska A, McCullough AJ, Feldstein A. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582–9.CrossRefGoogle Scholar
  14. 14.
    Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682–98.CrossRefGoogle Scholar
  15. 15.
    de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48:S104–12.CrossRefGoogle Scholar
  16. 16.
    Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629–40.CrossRefGoogle Scholar
  17. 17.
    Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21.CrossRefGoogle Scholar
  18. 18.
    Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65:S57–63.CrossRefGoogle Scholar
  19. 19.
    Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine–adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131:934–45.CrossRefGoogle Scholar
  20. 20.
    Baranova A, Randhawa M, Jarrar M, et al. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn. 2007;7:195–205.CrossRefGoogle Scholar
  21. 21.
    Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 2005;42:1175–83.CrossRefGoogle Scholar
  22. 22.
    McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol. 2006;17:170–5.CrossRefGoogle Scholar
  23. 23.
    Aller R, de Luis DA, Fernandez L, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci. 2008;53:1088–92.CrossRefGoogle Scholar
  24. 24.
    Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology. 2006;130:1848–52.CrossRefGoogle Scholar
  25. 25.
    Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498–504.CrossRefGoogle Scholar
  26. 26.
    Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403–9.CrossRefGoogle Scholar
  27. 27.
    Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab. 2004;89:1844–8.CrossRefGoogle Scholar
  28. 28.
    Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117–21.CrossRefGoogle Scholar
  29. 29.
    Le D, Marks D, Lyle E, et al. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc. 2007;21:1593–9.CrossRefGoogle Scholar
  30. 30.
    Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113–8.CrossRefGoogle Scholar
  31. 31.
    Pagano C, Soardo G, Pilon C, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab. 2006;91:1081–6.CrossRefGoogle Scholar
  32. 32.
    Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2006;64:679–83.CrossRefGoogle Scholar
  33. 33.
    Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol. 2008;43:1128–36.CrossRefGoogle Scholar
  34. 34.
    American Society for Bariatric Surgery, Society of American Gastrointestinal Endoscopic Surgeons. Guidelines for laparoscopic and open surgical treatment of morbid obesity. Obes Surg. 2000;10:378–9.CrossRefGoogle Scholar
  35. 35.
    Jackson AS, Pollock ML, Graves JE, et al. Reliability and validity of bioelectrical impedance in determining body composition. J Appl Physiol. 1988;64:529–34.CrossRefGoogle Scholar
  36. 36.
    Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285: 2486–97.CrossRefGoogle Scholar
  37. 37.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefGoogle Scholar
  38. 38.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefGoogle Scholar
  40. 40.
    Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefGoogle Scholar
  41. 41.
    Vega GL, Chandalia M, Szczepaniak LS, et al. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology. 2007;46:716–22.CrossRefGoogle Scholar
  42. 42.
    Charlton M, Angulo P, Chalasani N, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008;47:484–92. reviewer 1, last comment.CrossRefGoogle Scholar
  43. 43.
    Chalasani N, Crabb DW, Cummings OW, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771–6.CrossRefGoogle Scholar
  44. 44.
    Angulo P, Alba LM, Petrovic LM, et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol. 2004;41:943–9.CrossRefGoogle Scholar
  45. 45.
    Yalniz M, Bahcecioglu IH, Ataseven H, et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2006;2006:34295.CrossRefGoogle Scholar
  46. 46.
    Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310–5.CrossRefGoogle Scholar
  47. 47.
    Arun J, Clements RH, Lazenby AJ, et al. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg. 2006;16:1351–8.CrossRefGoogle Scholar
  48. 48.
    Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.CrossRefGoogle Scholar
  49. 49.
    Yoneda M, Iwasaki T, Fujita K, et al. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. Alcohol Clin Exp Res. 2007;31:S15–21.CrossRefGoogle Scholar
  50. 50.
    Liew PL, Lee WJ, Lee YC, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006;16:1584–93.CrossRefGoogle Scholar
  51. 51.
    Shimada M, Kawahara H, Ozaki K, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol. 2007;102:1931–8.CrossRefGoogle Scholar
  52. 52.
    Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151–6.CrossRefGoogle Scholar
  53. 53.
    Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430–7.CrossRefGoogle Scholar
  54. 54.
    Diamond FB Jr, Cuthbertson D, Hanna S, et al. Correlates of adiponectin and the leptin/adiponectin ratio in obese and non-obese children. J Pediatr Endocrinol Metab. 2004;17:1069–75.CrossRefGoogle Scholar
  55. 55.
    Perseghin G, Lattuada G, De Cobelli F, et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab. 2006;91:5122–5.CrossRefGoogle Scholar
  56. 56.
    Cho YK, Lee WY, Oh SY, et al. Factors affecting the serum levels of adipokines in Korean male patients with nonalcoholic fatty liver disease. Hepatogastroenterology. 2007;54:1512–6.PubMedGoogle Scholar
  57. 57.
    Chalasani N, Wilson L, Kleiner DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol. 2008;48:829–34.CrossRefGoogle Scholar
  58. 58.
    Wolf AM, Busch B, Kuhlmann HW, et al. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes Surg. 2005;15:228–37.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Marianna Argentou
    • 1
  • Dina G. Tiniakos
    • 2
    Email author
  • Menelaos Karanikolas
    • 3
  • Maria Melachrinou
    • 4
  • Maria G. Makri
    • 5
  • Christos Kittas
    • 2
  • Fotis Kalfarentzos
    • 1
  1. 1.Department of Surgery—Division of Nutritional Support and Morbid Obesity, Medical SchoolUniversity of PatrasPatrasGreece
  2. 2.Laboratory of Histology & Embryology, Medical SchoolNational & Kapodistrian University of AthensAthensGreece
  3. 3.Department of Anesthesiology and Critical Care Medicine, Medical SchoolUniversity of PatrasPatrasGreece
  4. 4.Department of Pathology, Medical SchoolUniversity of PatrasPatrasGreece
  5. 5.Department of Endocrinology, Medical SchoolUniversity of PatrasPatrasGreece

Personalised recommendations